Stoke Therapeutics, Inc. financial data

Symbol
STOK on Nasdaq
Location
Bedford, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 16 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 669% % 16%
Debt-to-equity 17% % -40%
Return On Equity -2% % 95%
Return On Assets -1.8% % 95%
Operating Margin -11% % 96%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59,150,790 shares 8.3%
Common Stock, Shares, Outstanding 58,921,999 shares 9%
Entity Public Float $592,000,000 USD 12%
Common Stock, Value, Issued $5,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 59,219,184 shares 9.6%
Weighted Average Number of Shares Outstanding, Diluted 59,219,184 shares 9.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $184,420,000 USD 404%
Research and Development Expense $137,922,000 USD 55%
General and Administrative Expense $55,452,000 USD 26%
Operating Income (Loss) $20,590,000 USD 80%
Nonoperating Income (Expense) $13,705,000 USD 11%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $39,625,000 USD -50%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $6,885,000 USD 92%
Earnings Per Share, Basic -0.12 USD/shares 93%
Earnings Per Share, Diluted -0.12 USD/shares 93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $84,220,000 USD -34%
Accounts Receivable, after Allowance for Credit Loss, Current $5,936,000 USD 256%
Other Assets, Current $3,895,000 USD 70%
Assets, Current $305,700,000 USD 31%
Property, Plant and Equipment, Net $3,146,000 USD -20%
Operating Lease, Right-of-Use Asset $3,101,000 USD -29%
Assets $418,434,000 USD 54%
Accounts Payable, Current $4,939,000 USD 98%
Liabilities, Current $57,875,000 USD 44%
Operating Lease, Liability, Noncurrent $1,141,000 USD -53%
Other Liabilities, Noncurrent $1,141,000 USD -54%
Liabilities $65,977,000 USD 55%
Accumulated Other Comprehensive Income (Loss), Net of Tax $543,000 USD
Retained Earnings (Accumulated Deficit) $497,715,000 USD -1.4%
Stockholders' Equity Attributable to Parent $352,457,000 USD 54%
Liabilities and Equity $418,434,000 USD 54%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $131,827,000 USD
Net Cash Provided by (Used in) Financing Activities $1,374,000 USD -20%
Net Cash Provided by (Used in) Investing Activities $13,632,000 USD 36%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 58,921,999 shares 9%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $146,833,000 USD
Deferred Tax Assets, Valuation Allowance $161,141,000 USD -2.7%
Deferred Tax Assets, Gross $161,141,000 USD -2.7%
Operating Lease, Liability $4,148,000 USD -13%
Depreciation $477,000 USD -15%
Payments to Acquire Property, Plant, and Equipment $152,000 USD 1167%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $6,191,000 USD 93%
Lessee, Operating Lease, Liability, to be Paid $4,481,000 USD -14%
Property, Plant and Equipment, Gross $13,292,000 USD 4.2%
Operating Lease, Liability, Current $3,007,000 USD 30%
Lessee, Operating Lease, Liability, to be Paid, Year Two $699,000 USD -73%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,249,000 USD 22%
Operating Lease, Weighted Average Discount Rate, Percent 0.1012 pure -0.88%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $333,000 USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year Three $533,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $87,588,000 USD 25%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $473,000 USD
Additional Paid in Capital $849,624,000 USD 18%
Share-based Payment Arrangement, Expense $32,238,000 USD 17%
Interest Expense $9,000 USD -65%